Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Cancer Vaccines01:30

Cancer Vaccines

367
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CUL5-mediated ubiquitination in cancer cell therapy: context-dependent roles, molecular networks, and emerging therapeutic avenues.

Frontiers in medicine·2026
Same author

Malignant mesothelioma of the tunica vaginalis testis: A case report.

Oncology letters·2026
Same author

A natural product-hybridization approach toward anticancer drug discovery: synthesis and antitumor evaluation of CTBC6, designed from sulforaphane and magnolol.

Bioorganic chemistry·2026
Same author

Comparison of surgical outcomes between lateral and posterior methods for retroperitoneoscopic adrenalectomy: insights from a single center's experience.

Frontiers in oncology·2026
Same author

Effects of Florfenicol on Intestinal Structure, Microbial Community and Antibiotic Resistance Genes in <i>Penaeus vannamei</i>.

Microorganisms·2026
Same author

Case Report: A rare case of unilateral renal clear cell carcinoma with synchronous contralateral ureteral metastasis.

Frontiers in oncology·2026
Same journal

Correction: Fukushima et al. Long-Term Immunogenicity of Rabies Pre-Exposure Prophylaxis in Japanese Adult Travelers: Comparison of Dosing Regimens. <i>Vaccines</i> 2025, <i>13</i>, 1169.

Vaccines·2026
Same journal

Access to Vaccines Among Asylum Seekers, Refugees, and Undocumented Migrants Across the Migratory Cycle in the European Union, European Economic Area, Switzerland and the United Kingdom: A Scoping Review.

Vaccines·2026
Same journal

Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies.

Vaccines·2026
Same journal

Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).

Vaccines·2026
Same journal

Post-Marketing Safety Surveillance of Influenza Vaccines in Anhui Province, China, 2016-2025.

Vaccines·2026
Same journal

Characteristics of Hypotonic-Hyporesponsive Episodes (HHEs) Following Childhood Vaccination: A 13-Year Analysis of Spontaneous Reports to the Dutch Pharmacovigilance Centre Lareb.

Vaccines·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

Bladder Cancer: Immunotherapy and Pelvic Lymph Node Dissection.

Zhongru Fan1, Junpeng Deng1, Yutao Wang2

  • 1Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Nanjing 211166, China.

Vaccines
|February 24, 2024
PubMed
Summary
This summary is machine-generated.

Immunotherapy offers a promising, less toxic treatment for bladder cancer. However, identifying predictive biomarkers and understanding the impact of pelvic lymph node dissection are crucial for improving patient outcomes.

Keywords:
bladder cancerimmunotherapypelvic lymph node dissection

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.5K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.8K

Related Experiment Videos

Last Updated: Jul 2, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.5K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.8K

Area of Science:

  • Urology
  • Oncology
  • Immunology

Background:

  • Bladder cancer is a common malignancy treated with radiation, chemotherapy, and surgery, which have limitations and side effects.
  • Immunotherapy is a novel approach that activates the patient's immune system to fight cancer, offering prolonged efficacy and fewer toxic side effects.
  • Current immunotherapies for bladder cancer include immune checkpoint inhibitors and cancer vaccines.

Purpose of the Study:

  • To discuss the challenges and potential of immunotherapy in bladder cancer treatment.
  • To highlight the need for predictive biomarkers for immunotherapy efficacy.
  • To examine the impact of pelvic lymph node dissection on immunotherapy outcomes.

Main Methods:

  • Review of current immunotherapy strategies for bladder cancer.
  • Discussion of challenges including patient variability in response and the role of pelvic lymph node dissection.
  • Analysis of existing literature on immune checkpoint inhibitors and cancer vaccines.

Main Results:

  • Immunotherapy efficacy varies significantly among patients, with a small subset responding.
  • Pelvic lymph node dissection may potentially reduce immunotherapy efficacy by damaging immune cells.
  • Predictive biomarkers are essential for optimizing immunotherapy selection and outcomes.

Conclusions:

  • Immunotherapy presents advantages for bladder cancer treatment, including reduced toxicity and durable responses.
  • Further research is required to identify predictive biomarkers and clarify the role of pelvic lymph node dissection.
  • Personalized treatment strategies considering individual patient characteristics are necessary to maximize immunotherapy benefits.